The Effectiveness of Interactive Patient Education on Adherence to Leprosy Medications in an Ambulatory Care Setting Indonesia: A Randomized Control Trial
DOI:
https://doi.org/10.3889/oamjms.2022.7634Keywords:
Interactive, Education, Adherence, Medications leprosy, Experimental designAbstract
BACKGROUND: Poor treatment adherence has been linked to recurrence and the development of antibiotic resistance in leprosy patients. Previous research has shown that structured health education programs improve treatment adherence in other patients, but similar research in leprosy patients is lacking.
AIM: This study aimed to assess the effect of interactive patient education on adherence to leprosy medications in an ambulatory care setting in Indonesia.
METHODS: A randomized controlled trial (RCT) was conducted between January and April 2021. The research was conducted at a public health center in West Papua, Indonesia. This RCT employed 1:1 randomization to allocate participants to one of two groups. Eligibility criteria included those aged over 18 years old and diagnosed with leprosy at least 6 months. An interactive patient education program included four intervention steps that lasted 1 month, with four sessions lasting 60–90 min each week. The Morisky Medication Adherence Scale was used to assess medication adherence. The difference-in-differences technique was used to evaluate the variances between T0 and T1 and T0 for the intervention versus control groups (DID).
RESULTS: Approximately, 200 participants agreed to join in this study (response rate = 72.5%). An interactive patient education program improved outcomes relative to the control at T1; medication adherence increased 0.11 (95% CI 0.01–0.25). At T2, improved outcomes relative to the control were observed in medication adherence (DID coefficient 0.31 (95% CI 0.10–0.59).
CONCLUSIONS: This study demonstrates that an interactive patient education program could effectively enhance medication adherence. Therefore, it is advised that health care professionals working with leprosy patients participate in the development of patient education programs and establish therapeutic partnerships with their patients.Downloads
Metrics
Plum Analytics Artifact Widget Block
References
World Health Organization. Guidelines for the Diagnosis, Treatment and Prevention of Leprosy. Geneva: World Health Organization; 2018. Available from: https://apps.who.int/iris/bitstream/handle/10665/274127/9789290226383-eng. pdf?ua=1 [Last accessed on 2020 Mar 15].
Lazo-Porras M, Prutsky GJ, Barrionuevo P, Tapia JC, Ugarte-Gil C, Ponce OJ, et al. World Health Organization (WHO) antibiotic regimen against other regimens for the treatment of leprosy: A systematic review and meta-analysis. BMC Infect Dis. 2020;20(1):1-14. DOI: https://doi.org/10.1186/s12879-019-4665-0
Franco-Paredes C, de Oca Sanchez GM, White C. Global leprosy status in 2020: Still losing touch. Ann Acad Med Singap. 2020;49(1):1-2. PMid:32200391 DOI: https://doi.org/10.47102/annals-acadmedsg.2019252
Kemenkes RI. Hapuskan Stigma dan Diskriminasi Terhadap Kusta. InfoDatin Pusat Data dan Informasi Kementrian Kesehatan RI. Jakarta: Kemenkes RI; 2018. p. 1-11.
Handog EB, Gabriel MTG, Co CC. Leprosy in the Philippines: A review. Int J Dermatol. 2011;50(5):573-81. https://doi.org/10.1111/j.1365-4632.2011.05044.x PMid:21506975 DOI: https://doi.org/10.1111/j.1365-4632.2011.05044.x
Chaptini C, Marshman G. Leprosy: A review on elimination, reducing the disease burden, and future research. Lepr Rev. 2015;86(4):307-15. PMid:26964426 DOI: https://doi.org/10.47276/lr.86.4.307
Williams MC. How can adherence with multi-drug therapy in leprosy be improved? Lepr Rev. 2005;76(2):160-1. PMid:16038249 DOI: https://doi.org/10.47276/lr.76.2.160
Cooreman E, Gillini L, Pemmaraju V, Shridar M, Tisocki K, Ahmed J, et al. Guidelines for the diagnosis, treatment and prevention of leprosy. World Health Organ. 2018;1:106.
Smith CS, Aerts A, Saunderson P, Kawuma J, Kita E, Virmond M. Multidrug therapy for leprosy: A game changer on the path to elimination. Lancet Infect Dis. 2017;17(9):e293-7. https://doi.org/10.1016/S1473-3099(17)30418-8 DOI: https://doi.org/10.1016/S1473-3099(17)30418-8
Rodrigues LC, Lockwood DN. Leprosy now: Epidemiology, progress, challenges, and research gaps. Lancet Infect Dis. 2011;11(6):464-70. https://doi.org/10.1016/S1473-3099(11)70006-8 PMid:21616456 DOI: https://doi.org/10.1016/S1473-3099(11)70006-8
Honrado ER, Tallo V, Balis AC, Chan GP, Cho SN. Noncompliance with the world health organization-multidrug therapy among leprosy patients in Cebu, Philippines: Its causes and implications on the leprosy control program. Dermatol Clin. 2008;26(2):221-9, vi. https://doi.org/10.1016/j.det.2007.11.007 PMid:18346553 DOI: https://doi.org/10.1016/j.det.2007.11.007
World Health Organization. Each Blister Pack Contains Treatment for 4 Weeks, No. 50. Geneva: World Health Organization; 2020.
Pepito VC, Amit AM, Samontina RE, Abdon SJ, Fuentes DN, Saniel OP. Variations in the clinical management of multibacillary leprosy patients in selected hospitals in Metro Manila. Acta Med Philipp. 2018;52(3):268-76. https://doi.org/10.47895/amp.v52i3.409 DOI: https://doi.org/10.47895/amp.v52i3.409
Pepito VC, Amit AM, Samontina RE, Abdon SJ, Fuentes DN, Saniel OP. Patterns and determinants of treatment completion and default among newly diagnosed multibacillary leprosy patients: A retrospective cohort study. Heliyon. 2021;7(6):e07279. https://doi.org/10.1016/j.heliyon.2021.e07279 PMid:34222685 DOI: https://doi.org/10.1016/j.heliyon.2021.e07279
Kumar A, Girdhar A, Chakma JK, Girdhar BK. WHO multidrug therapy for leprosy: Epidemiology of default in treatment in Agra district, Uttar Pradesh, India. Biomed Res Int. 2015;2015:705804. https://doi.org/10.1155/2015/705804 PMid:25705679 DOI: https://doi.org/10.1155/2015/705804
Delavar F, Pashaeypoor S, Negarandeh R. The effects of self-management education tailored to health literacy on medication adherence and blood pressure control among elderly people with primary hypertension: A randomized controlled trial. Patient Educ Couns. 2020;103(2):336-42. https://doi.org/10.1016/j.pec.2019.08.028 PMid:31451361 DOI: https://doi.org/10.1016/j.pec.2019.08.028
Moodley N, Saimen A, Zakhura N, Motau D, Setswe G, Charalambous S, et al. “They are inconveniencing us” - exploring how gaps in patient education and patient centred approaches interfere with TB treatment adherence: perspectives from patients and clinicians in the Free State Province, South Africa. BMC Public Health. 2020;20(1):454. https://doi.org/10.1186/s12889-020-08562-3 PMid:32252703 DOI: https://doi.org/10.1186/s12889-020-08562-3
Newman-Casey PA, Killeen OJ, Renner M, Robin AL, Lee P, Heisler M. Access to and experiences with, e-health technology among glaucoma patients and their relationship with medication adherence. Telemed J E Health. 2018;24(12):1026-35. https://doi.org/10.1089/tmj.2017.0324 PMid:29683401 DOI: https://doi.org/10.1089/tmj.2017.0324
Keshvari M, Farashbandi FZ, Geraei E. Modelling influential factors on customer loyalty in public libraries: A study of West Iran. Electron Libr. 2015;33(4):810-23. https://doi.org/10.1108/EL-10-2013-0185 DOI: https://doi.org/10.1108/EL-10-2013-0185
Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24(1):67-74. https://doi.org/10.1097/00005650-198601000-00007 PMid:3945130 DOI: https://doi.org/10.1097/00005650-198601000-00007
Wulff R, Abrahamsen B, Ejersted CA, Christensen PM, Brixen KT. Compliance with the treatment of osteoporosis with diphosphonates. A questionnaire among postmenopausal women. Ugeskr Laeger. 2004;166(1-2):49-53. PMid:14752994
Eiken P, Kolthoff N. Compliance with 10 years oral hormonal replacement therapy. Maturitas. 2002;41(2):81-6. https://doi.org/10.1016/s0378-5122(01)00246-8 PMid:11836038 DOI: https://doi.org/10.1016/S0378-5122(01)00246-8
Sarkadi A, Rosenqvist U. Experience-based group education in Type 2 diabetes: A randomised controlled trial. Patient Educ Couns. 2004;53(3):291-8. https://doi.org/10.1016/j.pec.2003.10.009 PMid:15186866 DOI: https://doi.org/10.1016/j.pec.2003.10.009
Grosset KA, Grosset DG. Effect of educational intervention on medication timing in Parkinson’s disease: a randomized controlled trial. BMC Neurol. 2007;7:20. https://doi.org/10.1186/1471-2377-7-20 PMid:17634109 DOI: https://doi.org/10.1186/1471-2377-7-20
Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing medication adherence. Cochrane database Syst Rev. 2008;2:CD000011. https://doi.org/10.1002/14651858.CD000011.pub4 PMid:25412402 DOI: https://doi.org/10.1002/14651858.CD000011.pub3
Dowd R, Recker RR, Heaney RP. Study subjects and ordinary patients. Osteoporos Int 2000;11:533-6. https://doi.org/10.1007/s001980070097 PMid:10982170 DOI: https://doi.org/10.1007/s001980070097
Barrett-Connor E, Wade S, Do T, Satram S, Stewart R, Gao G, et al. Treatment satisfaction and persistence among postmenopausal women on osteoporosis medications: 12-month results from POSSIBLE US (TM). Osteoporos Int. 2011;23(2):733-41. https://doi.org/10.1007/s00198-011-1620-3 PMid:21625886 DOI: https://doi.org/10.1007/s00198-011-1620-3
Downloads
Published
How to Cite
License
Copyright (c) 2022 Yayuk Nuryanti, Ruth Harriet Faidiban, Hosiana Sombuk, Ivonne Junita Fabanjo, Niluh Gede Susantie, Oktoviandi Sawaasemariay, Waode Suriani, Gidion Mansa (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
